title: Dopamine D3 and D4 receptor antagonists in the treatment of schizophrenia.
abstract: The findings that dopamine D3 and D4 receptors are highly expressed in limbic and cortical areas (D4 more than D3), and the fact that the atypical drug clozapine has preferential affinity for the D4 receptors have suggested an involvement of these receptors in schizophrenia. Subsequently, many pharmaceutical companies have pursued the approach of developing selective dopamine D3 or D4 antagonists as potential antipsychotics. This review will discuss the current status of selective dopamine D3 and D4 receptor antagonists for the treatment of schizophrenia.
authors.affiliation: Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden. kent.jardemark@fyfa.ki.se
authors.forename: Kent
authors.initials: K
authors.lastname: Jardemark
authors.forename: Marie-Louise
authors.initials: ML
authors.lastname: Wadenberg
authors.forename: Pernilla
authors.initials: P
authors.lastname: Grillner
authors.forename: Torgny H
authors.initials: TH
authors.lastname: Svensson
mesh_terms: D000818:Animals; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D018492:Dopamine Antagonists / Q000737:chemistry / Q000627:therapeutic use*; D065127:Dopamine D2 Receptor Antagonists; D006801:Humans; D017448:Receptors, Dopamine D2 / Q000096:biosynthesis; D050637:Receptors, Dopamine D3; D050638:Receptors, Dopamine D4; D012559:Schizophrenia / Q000188:drug therapy* / Q000378:metabolism
chemical_list: C493593:DRD3 protein, human; C493599:DRD4 protein, human; D018492:Dopamine Antagonists; D065127:Dopamine D2 Receptor Antagonists; D017448:Receptors, Dopamine D2; D050637:Receptors, Dopamine D3; D050638:Receptors, Dopamine D4